PARLIAMENTARY WRITTEN QUESTION
Valneva: Coronavirus (27 April 2021)

A COVID-19 vaccine will only be authorised once it has met robust standards on safety, effectiveness and quality through clinical trials and been authorised for use by the independent Medicines and Healthcare products Regulatory Agency (MHRA).

Once they have thoroughly reviewed the data, the MHRA seeks advice from the Government’s independent advisory body, the Commission on Human Medicines. They critically assess the data before advising on the safety, quality and effectiveness of any potential vaccine. While a vaccine is authorised by the MHRA, the Joint Committee on Vaccination and Immunisation will advise the Government about the use of the vaccine.

As such, if the Valneva vaccine is authorised by the MHRA and is advised for use, then it will be made available on the National Health Service.